Coherus Oncology, Inc. (NASDAQ: CHRS) is a Healthcare company (Biotechnology) with a market capitalization of $74M. The Maz Rating grades it against the other companies in its sector.
Coherus Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.48, Coherus Oncology, Inc. trades at 1.3x sales and 2.7x book value. Over the last twelve months it generated about $58M of revenue and a net loss of $163M. It runs a gross margin of 66.5%, an operating margin of -275.9% and a net margin of -252.0%. It shows return on equity of -239.6%, return on invested capital of -180.1% and a free cash flow yield of -331.5%. On the balance sheet: a debt-to-equity ratio of 2.75 and a current ratio of 1.47. Over the past 52 weeks the share price ranged from $0.43 to $2.62, with a beta of 1.03.
Coherus Oncology, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 14 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.